.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX29_Talquetamab.Talquetamab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX29_Talquetamab.Talquetamab| name: | Talquetamab |
| ATC code: | L01FX29 | route: | subcutaneous |
| n-compartments | 2 |
Talquetamab is a bispecific monoclonal antibody that targets both GPRC5D, a receptor highly expressed in multiple myeloma cells, and CD3 on T cells, redirecting T cells to kill malignant plasma cells. It is used for the treatment of relapsed or refractory multiple myeloma and has received accelerated approval in the United States.
Pharmacokinetic parameters are generally reported from clinical trial populations of adult patients with relapsed or refractory multiple myeloma.